TrumpRx drama collides with kids losing coverage

Washington's latest health-care soap opera

Sen. Elizabeth Warren says a Trump-signed law has already kicked 2 million-plus children off Medicaid and CHIP across the states, with huge drops cited in places like California, Texas, and Indiana. That's not just a policy debate — it's a real-world reminder that when Washington moves the goalposts, families feel it fast.

TrumpRx: cheaper meds, or just better branding?

Warren also went after TrumpRx, the administration's drug-cost pitch, arguing the math on the promised savings doesn't quite survive contact with a calculator. The site doesn't actually dispense medicines; it points people toward discounts and coupons, which is a little less "magic wand" and a little more "coupon folder from 2009."

Why pharma investors should care

The article name-checks several big drugmakers tied to TrumpRx's most-favored-nation pricing setup:

• AstraZeneca, Eli Lilly, Novo Nordisk, Pfizer, Amgen, and GSK are all in the mix
• Novartis was mentioned as a critic of MFN-style pricing, but not as part of the lineup
• The broader concern is that government pricing pressure can squeeze margins, shift patient demand, and keep the policy headline machine buzzing

For now, this is less about one company's earnings and more about a sector-wide reminder: in pharma, politics can hit the stock chart almost as hard as clinical data. Big picture: if Washington keeps leaning on drug pricing, the winners and losers may be decided in the Capitol before they ever get decided in the lab.